Viveo raises R$1.8 billion with IPO

Posted Friday, November 26th 2021
Viveo raises R$1.8 billion with IPO

In August, leading Brazilian medical supplies distribution company Viveo held its IPO at São Paulo-based stock exchange B3 and raised R$1.8 billion. The IPO included a primary offering of 35,140,562 common shares and a secondary offering of 59,085,356 common shares, which were priced at R$19.92 each.


Viveo was founded in 1996 by the Mafra family, who now controls the operation alongside the Bueno family, founders of the Amil group. Since 2017, the company’s growth was accelerated through several acquisitions, which included personal hygiene group Flexicotton, hospital supplies companies Biogenetix, Vitalab and Byogene, as well as a stake of pharmacotherapy company Far.Me, vaccines manufacturer Tecnocolg and disposable diapers manufacturer Cremer.


Davis Polk & Wardwell advised Viveo in its corporate, tax and investment management matters, and Machado Meyer Advogados (São Paulo) advised Viveo and the selling shareholders.


JP Morgan Securities, Itaú BBA USA Securities, BTG Pactual US Capital, UBS Securities, BofA Securities, Bradesco Securities and Safra Securities acted as international placement agents and hired Simpson Thacher & Bartlett to act in tax and capital markets discussions.


Stocche Forbes Advogados, respectively, advised Banco JP Morgan, Banco Itaú BBA, Banco BTG Pactual, Banco Bradesco BBI, Safra Bank, UBS Brasil Corretora de Exchange, Securities and Bank of America Merrill Lynch Banco Múltiplo as the coordinators of the local offering.